New Targeted Drug Approved for Low-Grade Glioma in Kids

(MedPage Today) -- The FDA granted accelerated approval to tovorafenib (Ojemda) for children 6 months and up with relapsed or refractory low-grade glioma and BRAF-altered tumors, the agency announced on Tuesday.
It represents the first systemic...